Early initiation of combination antiretroviral therapy in HIV-1 Infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages 1012-1019

  Bitnun, Ari ^a   Samson, Lindy ^b   Chun, Tae Wook ^c   Kakkar, Fatima ^d   Brophy, Jason ^b   Murray, Danielle ^c   Justement, Shawn ^c   Soudeyns, Hugo ^d   Ostrowski, Mario ^e   Mujib, Shariq ^f   Harrigan, P Richard ^g   Kim, John ^h   Sandstrom, Paul ^h   Read, Stanley E ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Child; Combination antiretroviral therapy; Eradication; HIV; Proviral DNA

Indexed keywords

HLA B ANTIGEN; HLA B58 ANTIGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; COCULTURE; COHORT ANALYSIS; EARLY CHILDHOOD INTERVENTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MITOGENESIS; MULTICENTER STUDY; NEWBORN; NEWBORN INFECTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SEROLOGY; SUSTAINED VIROLOGIC SUPPRESSION; TIME TO TREATMENT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION; ADULT; CANADA; CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; ISOLATION AND PURIFICATION; MALE; PROCEDURES; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84913586652     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu432     Document Type: Article

References (32)

1. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-35.
2. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
3. Goulder PJ,Walker BD. HIV and HLA class I: an evolving relationship. Immunity 2012; 37:426-40.
4. Panel on Antiretroviral Therapy and Medical Management of HIVInfected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed 15 May 2014.
5. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-8.
6. Blazkova J, Chun TW, Belay BW, et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 2012; 206:765-9.
7. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-8.
8. Meiklejohn DA, Karlsson RK, Karlsson AC, Chapman JM, Nixon DF, Schweighardt B. ELISPOT cell rescue. J Immunol Methods 2004; 288:135-47.
9. Brumme ZL, Chan KJ, DongW, et al. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS 2001; 15:2259-66.
10. Brumme ZL, Brumme CJ, Chui C, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007; 195:1694-704.
11. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-7.
12. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74:6984-91.
13. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004; 78:968-79.
14. Scott ZA, Chadwick EG, Gibson LL, et al. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol 2001; 167:7134-40.
15. Luzuriaga K, Chen YH, Ziemniak C, et al. Absent HIV-specific immune responses and replication-competent HIV reservoirs in perinatally infected youth treated from infancy: towards cure. In: Annual Conference of Retroviruses and Opportunistic Infections (CROI), Atlanta, GA, 2013.
16. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23:381-90.
17. Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012; 26:1483-90.
18. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28:1015-20.
19. Luzuriaga K, Tabak B, Garber M, et al. Reduced HIV reservoirs after early treatment HIV-1 proviral reservoirs decay continuously under sustained virologic control in early-treated HIV-1-infected children [published ahead of print]. J Infect Dis 2014; doi 10.1093/infdis/jiu297.
20. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24: 2803-8.
21. Okoye AA, Rohankhedkar M, Reyes M, et al. Early treatment in acute SIV infection limits the size and distribution of the viral reservoir (136LB). Top Antivir Med 2014; 22(e-1):68.
22. Vigano A, Trabattoni D, Schneider L, et al. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. J Pediatr 2006; 148:389-91.
23. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
24. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-51.
25. Forbes JC, Alimenti AM, Singer J, et al. A national review of vertical HIV transmission. AIDS 2012; 26:757-63.
26. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366:2368-79.
27. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/Perinatal GL.pdf. Accessed 15 May 2014.
28. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-20.
29. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-96.
30. Sanchez R, Portilla J, Gimeno A, et al. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. J Infect 2007; 54:159-66.
31. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003; 8:411-5.
32. Lo B, Grady C. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS 2013; 8:243-9.